Clinical Trials Browser

INDUSTRY × Melanoma × binimetinib × Clear all

NCT05926960 2026-03-09

PORTSIDE

Phase 2 Terminated

Melanoma, Skin Neoplasms

NCT04657991 2026-03-02

A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma

Phase 3 Active not recruiting

Melanoma, Skin Neoplasms

NCT01909453 2026-02-27

COLUMBUS

Phase 3 Completed

921 enrolled 48 charts 1 FDA

Melanoma, Neoplasm Metastasis, Neoplasms, Skin Diseases, Skin Neoplasms

NCT05355701 2026-02-03

A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.

Phase 1 Recruiting

CNSDermatologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Glioma, Melanoma, Thyroid Neoplasms

NCT03947385 2026-01-27

Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

Phase 1/2 Recruiting

DermatologicGastrointestinal

Uveal Melanoma, Melanoma, Colorectal Neoplasms

NCT04543188 2025-10-23

A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement

Phase 1 Terminated

65 enrolled 52 charts

CNSDermatologicThoracic

Brain Diseases, Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasms, Central Nervous System Neoplasms

NCT07022457 2025-08-03

UK-EnBiRiM

Melanoma

NCT05340621 2025-03-07

NAUTILUS: OKI-179 Plus Binimetinib in Patients with Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutated Melanoma (Phase 2)

Phase 1/2 Completed

Melanoma

NCT03864042 2024-09-27

Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors

Phase 1 Completed

56 enrolled 158 charts

Melanoma

NCT05810740 2024-09-19

Bioequivalence Binimetinib 3 x 15 mg and 45 mg Formulations

Phase 1 Completed

37 enrolled 25 charts

Melanoma

NCT02159066 2024-03-05

LOGIC-2

Phase 2 Completed

158 enrolled 40 charts

Melanoma

NCT01320085 2024-01-24

A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma

Phase 2 Completed

183 enrolled 35 charts

Melanoma, Hereditary Sensory and Autonomic Neuropathies

NCT05270044 2023-11-22

COLUMBUS-AD

Phase 3 Active not recruiting

Melanoma

NCT03911869 2023-05-31

POLARIS

Phase 2 Terminated

13 enrolled 55 charts

CNSDermatologic

Brain Neoplasms, Melanoma

NCT03878719 2023-04-03

Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients With Unresectable or Metastatic BRAF V600-mutant Melanoma

Phase 1 Terminated

Melanoma

NCT04759846 2023-02-21

Hepatic Impairment Study of Encorafenib in Combination With Binimetinib in BRAF Melanoma

Phase 1 Withdrawn

Melanoma

NCT05103891 2021-12-01

Relative Bioavailability of Binimetinib 3 x 15 mg and 45 mg Formulations

Phase 1 Unknown

Melanoma

NCT01763164 2021-03-22

Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma

Phase 3 Completed

402 enrolled 21 charts

Melanoma, Neoplasm Metastasis, Skin Diseases, Skin Neoplasms

NCT01801358 2020-09-16

A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma

Phase 1/2 Terminated

38 enrolled 31 charts

Uveal Melanoma, Melanoma